argenx SE (NASDAQ:ARGX) Shares Purchased by Capital World Investors

Capital World Investors lifted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,786,936 shares of the company's stock after purchasing an additional 86,687 shares during the period. Capital World Investors owned about 2.94% of argenx worth $1,099,002,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of argenx by 21.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock valued at $15,332,000 after buying an additional 4,445 shares during the period. GeoWealth Management LLC raised its holdings in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Altium Capital Management LLC purchased a new position in argenx in the fourth quarter worth approximately $6,150,000. CANADA LIFE ASSURANCE Co grew its holdings in argenx by 23.2% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 14,644 shares of the company's stock worth $8,997,000 after acquiring an additional 2,759 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after purchasing an additional 124,271 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Trading Up 1.7 %

Shares of NASDAQ:ARGX traded up $10.33 during midday trading on Friday, hitting $610.84. The stock had a trading volume of 114,799 shares, compared to its average volume of 307,633. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The stock has a 50 day moving average price of $598.76 and a two-hundred day moving average price of $607.23. The company has a market capitalization of $37.30 billion, a PE ratio of -694.29 and a beta of 0.60.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ARGX. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. William Blair reaffirmed an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Truist Financial reiterated a "buy" rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wedbush restated an "outperform" rating and set a $715.00 target price on shares of argenx in a research note on Friday, April 11th. Finally, Guggenheim increased their price target on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.